Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review

被引:0
作者
Fabrice Smieliauskas
Chun-Ru Chien
Chan Shen
Daniel M. Geynisman
Ya-Chen Tina Shih
机构
[1] The University of Chicago,Department of Health Studies
[2] China Medical University Hospital,Department of Radiation Oncology
[3] China Medical University,School of Medicine, College of Medicine
[4] The University of Texas MD Anderson Cancer Center,Department of Health Services Research
[5] The University of Texas MD Anderson Cancer Center,Department of Biostatistics
[6] Fox Chase Cancer Center,Department of Medical Oncology
[7] Temple Health,Section of Hospital Medicine, Department of Medicine, Program in the Economics of Cancer
[8] The University of Chicago,undefined
来源
PharmacoEconomics | 2014年 / 32卷
关键词
Imatinib; Sorafenib; Sunitinib; Erlotinib; Everolimus;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:651 / 680
页数:29
相关论文
共 257 条
[1]  
Sledge GW(2005)What is targeted therapy? J Clin Oncol 23 1614-1615
[2]  
Soria JC(2011)Added value of molecular targeted agents in oncology Ann Oncol 22 1703-1716
[3]  
Blay JY(2013)Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement Clin Pharmacokinet 52 399-414
[4]  
Spano JP(2013)Adherence to targeted oral anticancer medications Discov Med 15 231-241
[5]  
Pivot X(2008)NCCN Task Force Report: Oral chemotherapy J Natl Compr Cancer Netw 6 S1-S14
[6]  
Coscas Y(2013)Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma Leuk Lymphoma 54 683-687
[7]  
Khayat D(2010)Targeting histone deacetylases: development of vorinostat for the treatment of cancer Epigenomics 2 457-465
[8]  
Stuurman FE(2013)A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer Cancer Res 73 4599-4605
[9]  
Nuijen B(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957
[10]  
Beijnen JH(2012)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 239-246